Millipore Launches new Product Line for Virus Safety
Product News Jan 12, 2010
Millipore Corporation has announced the availability of its new Viresolve® Pro+ Solution. Millipore made the announcement at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
“The launch of Viresolve Pro+ Solution expands our industry-leading virus safety offerings, which help companies address increasingly diverse and difficult virus-removal challenges, improve the productivity of their manufacturing processes, and ensure the safety and quality of their products.”
“Virus safety is an increasingly critical issue in the biopharmaceutical industry and recent incidents of viral contamination have highlighted why effective virus safety solutions are so important for our customers,” said Jean-Paul Mangeolle, President of Millipore’s Bioprocess Division. “The launch of Viresolve Pro+ Solution expands our industry-leading virus safety offerings, which help companies address increasingly diverse and difficult virus-removal challenges, improve the productivity of their manufacturing processes, and ensure the safety and quality of their products.”
Biological drug products such as monoclonal antibodies and therapeutic proteins are manufactured using biological source material and production processes that can become contaminated with viruses. As a result, biopharmaceutical manufacturers are required to incorporate sufficient virus clearance steps into their manufacturing processes to ensure their products are free of virus contamination.
Millipore’s virus safety products provide customers with robust virus filtration, from process development to full-scale biopharmaceutical production. Viresolve Pro+ Solution strengthens Millipore’s offerings by providing a robust parvovirus clearance that works effectively at higher titer feedstreams. Parvoviruses are some of the smallest viruses found in nature, which makes them particularly difficult to remove in the manufacturing process.
Viresolve Pro+ Solution is available in a disposable flow path and increases the overall capacity and productivity of biopharmaceutical manufacturers’ virus removal operations. It is designed to fit both monoclonal antibody and therapeutic protein processes. It also includes a proprietary binary gas integrity test (BGT) to detect the presence of oversized pores or defects that can compromise a filter’s retention capability and cause contamination in the end product-providing a critical quality-control safeguard for the end user.